BACKGROUND: Sunitinib and pazopanib are both oral small molecule multityrosine kinase inhibitors (MTKI) used in the treatment of renal cell carcinoma (RCC). Hepatotoxicity or "liver injury" is the most important adverse effect of pazopanib administration, but little is known about the underlying mechanism. Liver injury may also occur in patients treated with sunitinib, but severe toxicity is extremely rare. Herein we report two new cases of severe liver injury induced by MTKI. Both cases are unique and exceptional. We assessed both cases for drug-induced liver injury (DILI) using the updated score Roussel Uclaf causality assessment method (RUCAM). The literature on potential pathogenic mechanisms and precautionary measures is reviewed. CASE PRESENTATION: A case of a metastatic RCC (mRCC) patient treated with pazopanib who had manifestation of severe liver injury is presented. These manifestations consisted of grade 4 alanine aminotransferase (ALT) increase and grade 4 hyperbilirubinemia. Alternate causes of acute or chronic liver disease were excluded. The patient gradually recovered from the liver injury and refused any further therapy for mRCC. The patient was diagnosed with acute myeloid leukemia (AML) two years later and eventually succumbed to the disease. The second case describes a mRCC patient treated with sunitinib for 3,5 years and fatal liver failure after 2 weeks of clarithromycin co-medication for acute bronchitis. CONCLUSIONS: Liver injury has been commonly observed in TKI-treated patients with unpredictable course. Management requires regular routine liver enzyme-monitoring and the collaboration of medical oncologist and hepatologist. There is an unmet medical need for a risk stratification and definition of predictive biomarkers to identify potential genetic polymorphisms or other factors associated with TKI-induced liver injury. Any potential unrecommended concomitant therapy has to be avoided.

2nd Department of Internal Medicine Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Deparment of Clinical Pharmacology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Hemato Oncology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Institute of Molecular and Translational Medicine Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

Zobrazit více v PubMed

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. PubMed

Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–2150. PubMed

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296. PubMed

Motzer R, Rini BI, McDermott DF, Frontera OA, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385. PubMed PMC

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. PubMed

Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. PubMed PMC

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. PubMed PMC

Motzer RJ, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study) J Clin Oncol. 2021;39(6):269. PubMed

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. PubMed

Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer. 2015;51(10):1293–1302. PubMed PMC

Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 2013;52(6):1202–1212. PubMed

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590. PubMed PMC

Demetri GD, Van OOsterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J,, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338. PubMed

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. PubMed

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107–2113. PubMed

Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol. 2013;18(6):1060–1069. PubMed

Aqsa A, Droubi S, Amarnath S, Al-Moussawi H, Abergel J. Sunitinib-induced acute liver failure. Case Rep Gastroenterol. 2021;15(1):17–21. PubMed PMC

Guillen SS, Meijer M, de Jongh FE. Lethal acute liver failure in a patient treated with sunitinib. BMJ Case Rep. 2016 doi: 10.1136/bcr-2015-213624. PubMed DOI PMC

Mermershtain W, Lazarev I, Shani-Shrem N, Ariad S. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma. Clin Genitourin Cancer. 2013;11(1):70–72. PubMed

Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009;43(4):761–766. PubMed

Taran A, Ignatov A, Smith B, Costa SD, Bischoff J. Acute hepatic failure following monotherapy with sunitinib for ovarian cancer. Cancer Chemother Pharmacol. 2009;63(5):971–972. PubMed

Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy. 2008;28(8):1066–1070. PubMed

Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol. 2014;77(6):929–938. PubMed PMC

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6(1):109. PubMed PMC

Spisarová M, Melichar B, Vitásková D, Študentová H. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. Future Oncol. 2021;17(3):241–254. PubMed

Shao J, Markowitz JS, Bei D, An G. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci. 2014;103(12):3810–3833. PubMed

Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503. PubMed

Karczmarek-Borowska B, Sałek-Zań A. Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn) 2015;19(2):87–92. PubMed PMC

Mingard C, Paech F, Bouitbir J, Krähenbühl S. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol. 2018;38(3):418–431. PubMed

Paech F, Bouitbir J, Krähenbühl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol. 2017;8:367. PubMed PMC

Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol. 2015;11(2):231–242. PubMed

EASL Clinical Practice Guidelines Drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261. PubMed

Danan G, Teschke R. Roussel Uclaf causality assessment method for drug-induced liver injury: present and future. Front Pharmacol. 2019;10:853. PubMed PMC

Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. PubMed PMC

Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–514. PubMed

Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–18.e5. PubMed

Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology. 2014;147(1):20–24. PubMed

Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen EP, et al. Pazopanib-induced hyperbilirubinemia is asociated with Gilbert s syndrome UGTIAI polymorphism. Br J Cancer. 2010;102:1371–1377. PubMed PMC

Motzer RJ, Johnson T, Choueiri TK, Deen KC, Xue Z, Pandite LN, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol. 2013;24(11):2927–2928. PubMed PMC

Henriksen JN, Bøttger P, Hermansen CK, Ladefoged SA, Nissen PH, Hamilton-Dutoit S, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18(1):62–8.e2. PubMed

Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, et al. HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer. Clin Cancer Res. 2016;22(6):1371–1377. PubMed PMC

Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics. 2013;14(5):541–554. PubMed

Wang YK, Yang XN, Liang WQ, Xiao Y, Zhao Q, Xiao XR, et al. A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. Xenobiotica. 2019;49(6):655–670. PubMed PMC

Paludetto MN, Stigliani JL, Robert A, Bernardes-Génisson V, Chatelut E, Puisset F, et al. Involvement of pazopanib and sunitinib aldehyde reactive metabolites in toxicity and drug–drug interactions in vitro and in patient samples. Chem Res Toxicol. 2020;33(1):181–190. PubMed

Vlenterie M, van Erp NP, van der Graaf WT. Promising management of pazopanib-induced liver toxicity. Acta Oncol. 2015;54(7):1064–1066. PubMed

Westgeest HM, van Erp NP, Honeywell RJ, Hoekstra R, Peters GJ, Verheul HM. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol. 2013;31(6):e83–e86. PubMed

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909–1916. PubMed PMC

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6:2012–2021. PubMed

Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220–4227. PubMed

Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43(5):443–453. PubMed

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22(23):5738–5746. PubMed

Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56(9):987–997. PubMed PMC

de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van DM, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37(3):331–338. PubMed

Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18(20):5780–5787. PubMed

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, et al. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet. 2017;56(3):293–303. PubMed

Jackson KD, Durandis R, Vergne MJ. Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors. Int J Mol Sci. 2018;19(8):2367. PubMed PMC

Amaya GM, Durandis R, Bourgeois DS, Perkins JA, Abouda AA, Wines KJ, et al. Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib. Chem Res Toxicol. 2018;31(7):570–584. PubMed PMC

Zhao Q, Zhang T, Xiao XR, Huang JF, Wang Y, Gonzalez FJ, et al. Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity. Br J Pharmacol. 2019;176(13):2162–2178. PubMed PMC

Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279–304. PubMed

Clarithromycin . LiverTox: clinical and research information on drug-induced liver injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PubMed

Bilbao-Meseguer I, Jose BS, Lopez-Gimenez LR, Gil MA, Serrano L, Castaño M, et al. Drug interactions with sunitinib. J Oncol Pharm Pract. 2015;21(1):52–66. PubMed

Szałek E, Karbownik A, Połom W, Matuszewski M, Sobańska K, Urjasz H, et al. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? Pharmacol Rep. 2012;64(6):1554–1559. PubMed

Azam C, Claraz P, Chevreau C, Vinson C, Cottura E, Mourey L, et al. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur J Clin Pharmacol. 2020;76(4):579–587. PubMed

Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106. PubMed

Bernal W, Lee WM, Wendon J, Larsen FS, Williams R. Acute liver failure: a curable disease by 2024? J Hepatol. 2015;62(1 Suppl):S112–S120. PubMed

Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Br J Clin Pharmacol. 2016;81(6):1021–1029. PubMed PMC

Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–64.e1. PubMed PMC

Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013;57(4):1542–1549. PubMed PMC

Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14(1):25–30. PubMed

Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: a meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594–599. PubMed

Charville GW, Padda SK, Sibley RK, Puthillath A, Kwo PY. Resolution of crizotinib-associated fulminant hepatitis following cessation of treatment. Case Reports Hepatol. 2018;2018:3413592. PubMed PMC

Patel T, Tarun T, Hudhud D, Krvavac A. Novel use of N-acetylcysteine in management of tyrosine kinase inhibitor induced acute liver injury. Cureus. 2019;11(11):e6251. PubMed PMC

Kreitman K, Nair SP, Kothadia JP. Successful treatment of crizotinib-induced fulminant liver failure: a case report and review of literature. Case Reports Hepatol. 2020;2020:8247960. PubMed PMC

Melichar B, Laco J, Fridrichova P, Simkovic M, Papajik T, Foretova L. Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases. Acta Oncol. 2012;51:136–138. PubMed

Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol. 2019;75(9):1309–1318. PubMed

Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83(10):2195–2204. PubMed PMC